Is Adagrasib available in China?

Adagrasib (Adagrasib) is a new type of small molecule targeted drug, mainly used to treat non-small cell lung cancer (NSCLC) carrying KRAS G12C mutation. KRAS G12CMutation is a common cancer driver gene mutation, especially common in lung cancer patients. The development of adagrasib represents an innovative solution to this difficult-to-treat genetic mutation.

Adagrasib is not currently available in the country, so patients cannot purchase it domestically and can only purchase adagrasib through overseas channels. Abroad, there is only the original American drug adagrasib, and the price is very high, as high as about 190,000 yuan.

Its mechanism of action is mainly through binding to the KRAS G12C mutated protein, blocking the abnormal cell signaling pathway caused by this mutation, effectively inhibiting the proliferation and survival of cancer cells. This specific targeting allows adagrasib to intervene in diseased cells more precisely, providing patients with a new treatment option.

Clinical trials have shown that adagrasib has significant efficacy in some patients with KRAS G12Cmutated non-small cell lung cancer. For those patients who have previously received other treatments and developed resistance, adagrasib provides a promising treatment path, extending patient survival and improving quality of life.

Although the use of adagrasib in the therapeutic field is still under in-depth research, as an innovative treatment, it has opened up a new treatment situation for patients with non-small cell lung cancer who carryKRAS G12C mutations. With the development of science and technology and a deeper understanding of cancer mechanisms, the research and application of adagrasib is expected to bring more hope and breakthroughs to lung cancer patients in the future.

xa0